Biotech - Spark Newswire

6 minute read

Keros Therapeutics Highlights Presentation Of Preclinical Data From ALK2 And KER-050 Hematology Programs At European Hematology Association EHA2021 Virtual Congress

Today, 9:48 PM

Multiple poster presentations demonstrate that ALK2 inhibition lowered hepcidin levels and improved iron homeostasis in preclinical models of anemia and iron overload. Poster presentation demonstrates that

KROS

1 minute read

Aptose Presents For Corporate Update Event

By Bill Haddad

Today, 9:48 PM

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, is

APTO

2 minute read

FDA
News

SWK Holdings Reports Its Wholly-Owned Subsidiary, Enteris BioPharma, Received $10M Milestone Payment From Cara Therapeutics For Licese Deal On Peptelligence Oral Formulation

By Benzinga Newsdesk

Today, 9:48 PM

SWK Holdings Corporation (NASDAQ:SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma,

CARA

2 minute read

FDA
News

Adamis Pharma Offers Update On Clinical Trial Start-Up Progress For Tempol In Treatment Of COVID-19

By Benzinga Newsdesk

Today, 9:48 PM

Activities Proceeding for Phase 2/3 Trial Examining the Effects of Tempol for the Treatment of COVID-19 SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced

ADMP

1 minute read

Incyte Announces FDA Has Extended New Drug Application Review Period For Ruxolitinib Cream For Treatment Of Atopic Dermatitis To Sept. 21 To Allow Time To Review Additional Analyses Submitted In Response To FDA’s Information Request

By Bill Haddad

Today, 9:48 PM

Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for ruxolitinib cream for the treatment of atopic

INCY

1 minute read

Tyme Stock Is Trading Higher On Pipeline Update After Strategic Review, Q4 Earnings

By Vandana Singh

Today, 9:48 PM

Tyme Technologies Inc (NASDAQ:TYME) announced a breast cancer trial with Georgetown University named OASIS. Enrollment is expected to start in Q3…

TYME

1 minute read

Novan’s Stock Surges As SB206 Can Potentially Shorten Duration Of Contagious Skin Disease

By Vandana Singh

Today, 9:48 PM

Novan Inc (NASDAQ:NOVN) has announced positive topline efficacy and safety results from the B-SIMPLE4 Phase 3 trial evaluating SB206, a topical…

NOVN

1 minute read

Orthofix To Present At JMP Securities Life Sciences Conference Jun. 16

By Bill Haddad

Today, 9:48 PM

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will

OFIX

4 minute read

FDA
News

Forma Therapeutics Highlights Presentation Of New Phase 1 Data On Etavopivat At European Hematology Association Congress

By Benzinga Newsdesk

Today, 9:48 PM

Clinical results demonstrated durable improvement in hematologic and hemolytic markers, supporting the potential for improvement of red blood cell functional health in those with sickle cell disease Initial results from

FMTX

2 minute read

Autolus Therapeutics Highlights Presentation Of AUTO1 Data At European Hematology Association Virtual Congress 2021

By Bill Haddad

Today, 9:48 PM

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a poster presentation related to AUTO1 (obecabtagene

AUTL